Immunogen | IMGN - مصروفات التشغيل



مصروفات التشغيل تغيير تاريخ
AbbVie USD 10.81B 13.45B 2025-12
Agios Pharmaceuticals USD 141.54M 11.8M 2025-12
Amgen USD 5.9B 773M 2025-12
Astellas Pharma JPY 436.66B 16.75B 2025-12
AstraZeneca USD 12.53B 4.16B 2025-12
Bristol-Myers Squibb USD 8.3B 10.25B 2025-12
Eli Lilly USD 10.31B 1.09B 2025-12
Emergent BioSolutions USD 555.9M 242.7M 2023-06
Exelixis USD 362.75M 21.35M 2025-12
Halozyme Therapeutics USD 211.07M 74.73M 2025-12
Heron Therapeutics USD 40.55M 1.46M 2025-12
Intrexon USD 61.56M 26.1M 2024-06
Karyopharm Therapeutics USD 61.82M 3.24M 2024-12
MacroGenics USD 53.32M 13.68M 2025-12
Nektar Therapeutics USD 85.09M 109.3M 2025-09
Novartis USD 9.8B 23M 2025-12
Pfizer USD 12.91B 79.89B 2025-12
Regeneron Pharmaceuticals USD 2.99B 27.97B 2025-12
Roche Holding CHF 21.01B 10.84B 2025-12
Sanofi EUR 10.71B 1.32B 2025-12